RECRUITING

A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers

Description

This is a multicenter randomized controlled trial that assesses the efficacy of a decisional intervention \[University of Rochester-Geriatric Oncology assessment for Acute myeloid Leukemia (UR-GOAL)\] compared to an attention control.

Conditions

OncologyMyeloid Leukemia, AcuteCancer
Talk to us

Related Conditions:

OncologyMyeloid Leukemia, AcuteCancer

Study Overview

On this page

Study Details

Study overview

This is a multicenter randomized controlled trial that assesses the efficacy of a decisional intervention \[University of Rochester-Geriatric Oncology assessment for Acute myeloid Leukemia (UR-GOAL)\] compared to an attention control.

A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers

A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers

Condition
Oncology
Intervention / Treatment

-

Contacts and Locations

Birmingham

University of Alabama at Birmingham, Division of Hematology and Oncology, Birmingham, Alabama, United States, 35233

Rochester

University of Rochester Medical Center, Rochester, New York, United States, 14642

Chapel Hill

University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States, 27514

Winston-Salem

Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Section of Hematology/Oncology, Winston-Salem, North Carolina, United States, 27157

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age ≥60 years (from date of consent, confirmed on electronic medical records)
  • * A new diagnosis of AML
  • * Diagnosis can be based on the International Consensus Classification or World Health Organization
  • * Myeloid sarcoma is allowed
  • * AML with central nervous system involvement is allowed
  • * Cancer-directed treatment has not started
  • * Treatment to temporarily decrease white blood cells is acceptable; these may include hydroxyurea, leukapheresis, or cytarabine
  • * Intrathecal chemotherapy is acceptable
  • * The patient's oncologist has been or will be enrolled on the study
  • * English or Spanish-speaking
  • * Patients without a caregiver will still be eligible to participate in the study Exclusion criteria
  • * A diagnosis of acute promyelocytic leukemia
  • * Patients with psychiatric or cognitive conditions which the treating oncologist believes prohibits informed consent or compliance with study procedures
  • * Prior cancer-directed treatment for AML

Ages Eligible for Study

60 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Rochester,

Study Record Dates

2030-06-01